-
Syndax Announces FDA Clearance of IND Application for Targeted Menin Inhibitor
americanpharmaceuticalreview
July 11, 2019
Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R
-
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use
drugs
June 03, 2019
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use.
-
First PI3K inhibitor for breast cancer approved by FDA
europeanpharmaceuticalreview
May 30, 2019
The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer.
-
IL-18 inhibitor drug holds great potential for inflammatory diseases
europeanpharmaceuticalreview
April 26, 2019
An international team of researchers has identified the key role that IL-18 protein plays in Still’s disease, making it a prime candidate for IL-18 inhibitor drug that is proving promising in current trials.
-
AACR: Bayer posts early clinical data on follow-up to Loxo's Vitrakvi
fiercebiotech
April 03, 2019
Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology.
-
CStone received IND approval in China for HDAC6 inhibitor CS3003
en-cphi.cn
March 13, 2019
Cstone announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China.
-
Groundbreaking Memory Research Shows Amazonian Plant Extract PTI-00703 Cat's Claw as Potent Inhibitor and Reducer of Both Brain Plaques and Tangles
en-cphi.cn
March 06, 2019
Scientific Reports recently published a landmark research paper which has immediate favorable implications for brain health and memory loss in the aging brain.
-
Morphic and Janssen collaboratively develop integrin therapies
pharmaceutical-technology
February 26, 2019
Biotechnology company Morphic Therapeutic has formed a research and collaboration alliance with Johnson & Johnson subsidiary Janssen for the discovery and development of new integrin therapeutics....
-
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
-
Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases
pharmafocusasia
December 13, 2018
Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the company’s lead candidate, RDN-929, a potent and selective HDAC-CoREST inhibitor.